ZAGREB, Feb 25 (Hina) - The pharmaceutical company Pliva on Monday announced it bought the Danish privately owned pharmaceutical company "2K Pharmaceuticals A/S" for a total of EUR4.1 million. Founded in 2000, the Danish company's
businesses primarily focuses on generic and niche products. Its first products were placed on market in August 2001, and during that year the company launched eight generic products from therapeutic areas of the cardiovascular and central nervous systems. The value of the Danish company, Pliva's official says, is in the ownership of registration files and licences, expert management and personnel with knowledge and experience in Nordic markets, and established relations with consumers built in a relatively short period. The growth potentials derive from a portfolio of new products under development. The transaction does not include the purchase of production facilities.
ZAGREB, Feb 25 (Hina) - The pharmaceutical company Pliva on Monday
announced it bought the Danish privately owned pharmaceutical
company "2K Pharmaceuticals A/S" for a total of EUR4.1 million.
Founded in 2000, the Danish company's businesses primarily focuses
on generic and niche products. Its first products were placed on
market in August 2001, and during that year the company launched
eight generic products from therapeutic areas of the
cardiovascular and central nervous systems.
The value of the Danish company, Pliva's official says, is in the
ownership of registration files and licences, expert management
and personnel with knowledge and experience in Nordic markets, and
established relations with consumers built in a relatively short
period. The growth potentials derive from a portfolio of new
products under development. The transaction does not include the
purchase of production facilities.
By acquiring the Danish company, Pliva gains direct access to all
highly developed Nordic countries, which have a high
pharmaceutical consumption per capita. Also, Pliva's presence in
Denmark as in a EU referent member, owing to the practice of mutual
recognition (MRP), enables the accelerated registration process in
other western European countries and the reduction of time required
for the placement of products onto the market.
(hina) np